Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Reserpine
Drug ID BADD_D01926
Description An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.
Indications and Usage For the treatment of hypertension
Marketing Status approved; investigational
ATC Code C02AA02
DrugBank ID DB00206
KEGG ID D00197
MeSH ID D012110
PubChem ID 5770
TTD Drug ID D0J4JM
NDC Product Code 49452-6217; 71052-422; 17359-1000
UNII 8B1QWR724A
Synonyms Reserpine | Rausedil | Rausedyl | Serpasil | Raunervil | V-Serp | V Serp | Raupasil | Serpivite
Chemical Information
Molecular Formula C33H40N2O9
CAS Registry Number 50-55-5
SMILES COC1C(CC2CN3CCC4=C(C3CC2C1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)O C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Angina pectoris24.04.04.002; 02.02.02.002--
Anxiety19.06.02.002--
Arrhythmia02.03.02.001--Not Available
Bradycardia02.03.02.002--Not Available
Breast engorgement21.05.05.002; 18.08.02.001--Not Available
Deafness04.02.01.001--Not Available
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dry mouth07.06.01.002--
Dyspnoea02.11.05.003; 22.02.01.004--
Dysuria20.02.02.002--
Epistaxis22.04.03.001; 24.07.01.005--
Extrapyramidal disorder17.01.02.007--
Glaucoma06.03.01.002--
Gynaecomastia21.05.04.003; 05.05.02.003--
Headache17.14.01.001--
Hyperchlorhydria07.11.03.001--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Loss of consciousness17.02.04.004--Not Available
Myalgia15.05.02.001--
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Nightmare19.02.03.003--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Optic atrophy06.09.02.001--Not Available
Pain08.01.08.004--
Parkinsonism17.01.05.003--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene